RESUMO
Immunosuppressed patients are at higher risk for developing herpes zoster (HZ), and neurological complications are frequent in them. However, the influence of immunosuppression (IS) on the severity and prognosis of neurological complications of varicella-zoster virus (VZV) reactivation is unknown. We studied retrospectively patients with neurological complications due to VZV reactivation who attended our hospital between 2004 and 2019. We aimed to assess the clinical spectrum, potential prognostic factors, and the influence of the immune status on the severity of neurological symptoms. A total of 98 patients were included (40% had IS). Fifty-five patients (56%) had cranial neuropathies which included Ramsay-Hunt syndrome (36 patients) and cranial multineuritis (23 patients). Twenty-one patients developed encephalitis (21%). Other diagnosis included radiculopathies, meningitis, vasculitis, or myelitis (15, 10, 6, and 4 patients, respectively). Mortality was low (3%). At follow-up, 24% of patients had persistent symptoms although these were usually mild. IS was associated with severity (defined as a modified Rankin scale greater than 2) (odds ratio, 4.23; 95% confidence interval, 1.74-10.27), but not with prognosis. Shorter latency between HZ and neurologic symptoms was the only factor associated with an unfavorable course (death or sequelae) (odds ratio, 0.82; 95% confidence interval, 0.71-0.95). In conclusion, the clinical spectrum of neurological complications in VZV reactivation is wide. Mortality was low and sequelae were mild. The presence of IS may play a role on the severity of neurological symptoms, and a shorter time between HZ and the onset of neurological symptoms appears to be a negative prognostic factor.
Assuntos
Encefalite por Varicela Zoster/imunologia , Herpes Zoster da Orelha Externa/imunologia , Herpes Zoster/imunologia , Herpesvirus Humano 3/patogenicidade , Imunossupressores/efeitos adversos , Neurite (Inflamação)/imunologia , Radiculopatia/imunologia , Idoso , Idoso de 80 Anos ou mais , Encefalite por Varicela Zoster/complicações , Encefalite por Varicela Zoster/diagnóstico , Encefalite por Varicela Zoster/mortalidade , Feminino , Herpes Zoster/complicações , Herpes Zoster/diagnóstico , Herpes Zoster/mortalidade , Herpes Zoster da Orelha Externa/diagnóstico , Herpes Zoster da Orelha Externa/etiologia , Herpes Zoster da Orelha Externa/mortalidade , Humanos , Terapia de Imunossupressão , Masculino , Meningite Viral/diagnóstico , Meningite Viral/etiologia , Meningite Viral/imunologia , Meningite Viral/mortalidade , Pessoa de Meia-Idade , Mielite/diagnóstico , Mielite/etiologia , Mielite/imunologia , Mielite/mortalidade , Neurite (Inflamação)/diagnóstico , Neurite (Inflamação)/etiologia , Neurite (Inflamação)/mortalidade , Prognóstico , Radiculopatia/diagnóstico , Radiculopatia/etiologia , Radiculopatia/mortalidade , Estudos Retrospectivos , Índice de Gravidade de Doença , Análise de Sobrevida , Vasculite/diagnóstico , Vasculite/etiologia , Vasculite/imunologia , Vasculite/mortalidade , Ativação Viral/efeitos dos fármacos , Latência Viral/efeitos dos fármacosRESUMO
Herpes zoster encephalitis (HZE) is a rare complication of varicella zoster virus (VZV) infection. We report two cases of HZE in solid organ transplant (SOT) recipients and review 10 other cases in the literature. In this review, rash was present in 67% of cases. Despite the absence of a rash, high clinical suspicion for HZE is necessary and empiric antiviral therapy should be considered. While with variable outcome, it was associated with high mortality rate of 42%. Prompt initiation of antiviral therapy remains crucial in decreasing morbidity and mortality from this fatal disease.
Assuntos
Encefalite por Varicela Zoster/diagnóstico , Herpes Zoster/complicações , Transplante de Órgãos/efeitos adversos , Aciclovir/uso terapêutico , Idoso , Antivirais/uso terapêutico , Encefalite por Varicela Zoster/etiologia , Encefalite por Varicela Zoster/mortalidade , Humanos , Hospedeiro Imunocomprometido , Masculino , TransplantadosRESUMO
The aim of the study was to describe the clinical and epidemiological characteristics of the central nervous system (CNS) infection by varicella zoster virus (VZV) in patients older than 65 years in a tertiary community hospital. We retrospectively analysed the results of cerebrospinal fluid (CSF) testing in patients older than 65 years between 2007 and 2014 with clinically suspected VZV infection with CNS involvement. Patients whose CSF samples were positive for VZV DNA were included, as were those with negative results who simultaneously presented herpes zoster and CSF or magnetic resonance imaging findings suggestive of CNS infection, and in whom other possible aetiologies had been ruled out. The study included 280 patients. The disease was considered to be caused by a VZV infection in 32 patients (11.4%), of which 23 cases were virologically confirmed (detection of VZV DNA in CSF). The most frequent diagnosis of the patients with VZV CNS infection was encephalitis (83.3%), followed by meningitis (13.3%) and cerebellitis (3.3%). The mean annual incidence of VZV CNS infection was 3.0 cases per 100,000 inhabitants. VZV was the most common cause of encephalitis and viral meningitis, ahead of herpes simplex virus (n = 9). At the time of discharge, 12 (40%) patients showed neurological sequelae. Five patients (20%) died during hospitalization, all with encephalitis. Patients with a fatal outcome had significantly higher median age and longer delay before initiating acyclovir. In conclusion, VZV was the first cause of encephalitis in our elderly population. Despite acyclovir treatment, there was a high rate of case fatality and sequelae at discharge.
Assuntos
DNA Viral/líquido cefalorraquidiano , Encefalite por Varicela Zoster/epidemiologia , Herpesvirus Humano 3/patogenicidade , Meningite Viral/epidemiologia , Infecção pelo Vírus da Varicela-Zoster/epidemiologia , Aciclovir/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Antivirais/uso terapêutico , Sistema Nervoso Central/patologia , Sistema Nervoso Central/virologia , Encefalite por Varicela Zoster/diagnóstico por imagem , Encefalite por Varicela Zoster/tratamento farmacológico , Encefalite por Varicela Zoster/mortalidade , Feminino , Herpesvirus Humano 3/efeitos dos fármacos , Herpesvirus Humano 3/fisiologia , Humanos , Incidência , Imageamento por Ressonância Magnética , Masculino , Meningite Viral/diagnóstico por imagem , Meningite Viral/tratamento farmacológico , Meningite Viral/mortalidade , Estudos Retrospectivos , Espanha/epidemiologia , Análise de Sobrevida , Infecção pelo Vírus da Varicela-Zoster/diagnóstico por imagem , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/mortalidadeRESUMO
Varicella zoster virus (VZV) is a leading cause of acute viral encephalitis but little is known about its clinical, biological and imaging features. Furthermore, the most favourable treatment regimen has not been determined. We studied a prospective cohort of 20 HIV-negative patients presenting with acute VZV encephalitis caused by primary infection or reactivation. VZV was identified in 16 of 20 cases by PCR detection of the DNA in the cerebrospinal fluid. The four remaining cases occurred during or soon after a VZV rash. The median age of the 17 adults was 76 (19-86) years; the three other patients were children (0.5-5 years). Three patients were immunocompromised. Nine adult patients presented with a rash. Eighteen patients presented with fever and an acute encephalitic syndrome: diffuse brain dysfunction, focal neurological signs, seizures and cranial nerve palsies. Three patients presented with either ventricular or subdural haemorrhage, one with myelitis, and one with asymptomatic stenosis of the middle cerebral artery. The imaging was either normal or revealed non-specific abnormalities such as cortical atrophy but no evidence of stroke. All patients were given acyclovir at various dosages and durations but the case fatality rate remained high (15%) and sequelae were frequently observed either at discharge or at follow-up 3 years later.